Body Composition

Retatrutide

5mg · Lyophilized Powder · 4,731 Da

VIAL SIZE

$80.00 CAD

Retatrutide is an investigational triple-receptor agonist peptide (targets GLP-1, GIP, and glucagon receptors) under development for obesity and type 2 diabetes. Phase 2 trials demonstrated remarkable weight-loss efficacy, with patients losing up to 24% of body weight at 48 weeks on higher doses. The glucagon receptor component drives increased energy expenditure and hepatic fat oxidation, differentiating Retatrutide from dual-agonist compounds. Its modified structure provides a six-day half-life suitable for once-weekly research protocols.

Research Applications

•Triple receptor agonism (GIP/GLP-1/Glucagon)

•Significant metabolic recomposition

•Appetite regulation via central satiety

•Enhanced energy expenditure

•Hepatic fat reduction

•Improved glycaemic markers

VIAL5 / 10 / 20 / 30 / 40 / 50 mg

PURITY≥99% (HPLC + LC-MS)

FORMLyophilized powder

STORAGE-20°C (long-term)

RECON1 mL BAC water (5mg/10mg) / 3 mL (30mg) / 6 mL (40mg) / 7.5 mL (50mg)

USEResearch only

VIEW DOSING PROTOCOL →

All products sold by JA Performance Peptides are intended strictly for laboratory research purposes and are not approved for human consumption, veterinary use, or therapeutic application. Not for human use.